Literature DB >> 3221041

Development of thyroid disease in patients with primary and secondary Sjögren's syndrome.

A Loviselli1, A Mathieu, R Pala, S Mariotti, S Cau, C Marongiu, A P Mazzoleni, P Maggio, E Martino.   

Abstract

Autoimmune thyroid disease associated to Sjögren syndrome (SS) may be defined by serological and functional abnormalities. We studied the prevalence of serum anti-thyroid autoantibodies and the development of thyroid functional defects by a follow-up investigation in patients with primary (pSS) and secondary SS (sSS). In keeping with previous literature data, our findings confirmed an increased prevalence of thyroid autoimmune phenomena in the whole series of patients with SS. In addition, evidence was provided for a greater incidence of serological and functional thyroid abnormalities in pSS when compared to sSS. Follow-up study also showed that the rate of thyroid autoimmune disease development was higher in pSS than in sSS. The appearance of circulating anti-thyroid antibodies was particularly frequent in patients with preexisting antibodies against extractable nuclear antigens (anti-ENA). These data indicate the need for a careful monitoring of thyroid function in SS patients, with particular regard to those with pSS and positive anti-ENA tests.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3221041     DOI: 10.1007/BF03350206

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  Anti-thyroid peroxidase antibody in patients with autoimmune thyroid disease: possible identity with anti-microsomal antibody.

Authors:  L Portmann; N Hamada; G Heinrich; L J DeGroot
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

2.  Genetic differences between primary and secondary sicca syndrome.

Authors:  H M Moutsopoulos; D L Mann; A H Johnson; T M Chused
Journal:  N Engl J Med       Date:  1979-10-04       Impact factor: 91.245

Review 3.  Insulin-dependent diabetes mellitus: the initial lesion.

Authors:  G F Cahill; H O McDevitt
Journal:  N Engl J Med       Date:  1981-06-11       Impact factor: 91.245

Review 4.  Primary Sjogren syndrome: clinical and immunopathologic features.

Authors:  R I Fox; F V Howell; R C Bone; P Michelson
Journal:  Semin Arthritis Rheum       Date:  1984-11       Impact factor: 5.532

5.  Spontaneous hypothyroidism in symptomless autoimmune thyroiditis. A long-term follow-up study.

Authors:  A Gordin; B A Lamberg
Journal:  Clin Endocrinol (Oxf)       Date:  1981-12       Impact factor: 3.478

6.  Comparison of serum thyroid microsomal and thyroid peroxidase autoantibodies in thyroid diseases.

Authors:  S Mariotti; S Anelli; J Ruf; R Bechi; B Czarnocka; A Lombardi; P Carayon; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1987-11       Impact factor: 5.958

7.  Isolation of intact Sm/RNP antigens from rabbit thymus.

Authors:  P B Billings; S O Hoch
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

8.  Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases.

Authors:  B Czarnocka; J Ruf; M Ferrand; P Carayon; S Lissitzky
Journal:  FEBS Lett       Date:  1985-10-07       Impact factor: 4.124

9.  Natural history of autoimmune thyroiditis.

Authors:  W M Tunbridge; M Brewis; J M French; D Appleton; T Bird; F Clark; D C Evered; J G Evans; R Hall; P Smith; J Stephenson; E Young
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24
View more
  2 in total

1.  Vitamin D Deficiency in Primary Sjögren's Syndrome: Association with Clinical Manifestations and Immune Activation Markers.

Authors:  Panagiotis Athanassiou; Clio Mavragani; Lambros Athanassiou; Ifigenia Kostoglou-Athanassiou; Michael Koutsilieris
Journal:  Mediterr J Rheumatol       Date:  2022-03-31

2.  Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren's syndrome: a case-control study.

Authors:  R Tunc; M S Gonen; O Acbay; V Hamuryudan; H Yazici
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.